MedGenome has taken a majority stake in Gujarat-based Green Cross Genetics Lab, a chain with three decades of diagnostic service. This move expands MedGenome's reach into western India through 17 laboratories and 35 collection centers. The partnership fuses traditional pathology with advanced genomics to improve disease detection across underserved regions.
Established Network Meets Cutting-Edge Genomics
Green Cross Genetics Lab, founded by Vinod Patel, has built trust over 30 years by delivering reliable pathology services under senior experts. Its operations span Gujarat with a portfolio of over 800 diagnostic tests and a team exceeding 500 professionals. MedGenome, operator of South Asia's largest CAP-accredited multiomics lab, brings AI-driven genetic analysis that aids clinicians in managing complex conditions.
Dr. Vedam Ramprasad, MedGenome's CEO, emphasized the fit: this alliance strengthens presence in Gujarat and advances affordable omics solutions in Tier 2 and Tier 3 cities. Green Cross promoters retain leadership to guide expansion. Vinod Patel, promoter and director, noted the synergy of infrastructure, technology, and clinical expertise with MedGenome's genomics platform.
Broadening Access to Precision Diagnostics
The collaboration integrates genomics into routine diagnostics, offering actionable tests for patients nationwide. Traditional pathology chains like Green Cross provide volume and local trust, while genomics firms such as MedGenome add molecular precision for early detection of hereditary diseases and cancers. This model addresses India's fragmented healthcare, where advanced testing often concentrates in metros.
Implications for India's Healthcare Landscape
India's diagnostics sector grows amid rising chronic disease burdens, yet rural and semi-urban areas lack genomic tools. Partnerships like this scale high-tech services through existing networks, potentially lowering costs and wait times. MedGenome aims to elevate Indian genomics globally by innovating scalable solutions. As precision medicine gains ground, such investments signal a shift toward data-informed care, benefiting clinicians and patients with comprehensive offerings.
